These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29133496)

  • 1. Factors Influencing Allopurinol Initiation in Primary Care.
    Clarson LE; Hider SL; Belcher J; Roddy E; Mallen CD
    Ann Fam Med; 2017 Nov; 15(6):557-560. PubMed ID: 29133496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment.
    Vargas-Santos AB; Peloquin CE; Zhang Y; Neogi T
    JAMA Intern Med; 2018 Nov; 178(11):1526-1533. PubMed ID: 30304329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
    Robinson PC; Taylor WJ; Dalbeth N
    J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
    Singh JA; Yang S; Saag KG
    J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Hill EM; Sky K; Sit M; Collamer A; Higgs J
    J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gout characteristics associate with depression, but not anxiety, in primary care: Baseline findings from a prospective cohort study.
    Prior JA; Mallen CD; Chandratre P; Muller S; Richardson J; Roddy E
    Joint Bone Spine; 2016 Oct; 83(5):553-8. PubMed ID: 27068619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of allopurinol use on urate concentration and cardiovascular outcome.
    Wei L; Mackenzie IS; Chen Y; Struthers AD; MacDonald TM
    Br J Clin Pharmacol; 2011 Apr; 71(4):600-7. PubMed ID: 21395653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
    Keith MP; Gilliland WR
    Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allopurinol initiation and all-cause mortality in the general population.
    Dubreuil M; Zhu Y; Zhang Y; Seeger JD; Lu N; Rho YH; Choi HK
    Ann Rheum Dis; 2015 Jul; 74(7):1368-72. PubMed ID: 24665118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study.
    Dennison EM; Rubin KH; Schwarz P; Harvey NC; Bone KW; Cooper C; Abrahamsen B
    Arch Osteoporos; 2015; 10():36. PubMed ID: 26481934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-titration of allopurinol in patients with gout.
    Jennings CG; Mackenzie IS; Flynn R; Ford I; Nuki G; De Caterina R; Riches PL; Ralston SH; MacDonald TM;
    Semin Arthritis Rheum; 2014 Aug; 44(1):25-30. PubMed ID: 24560169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.
    Edwards NL
    Am J Med; 2006 Nov; 119(11 Suppl 1):S29-31. PubMed ID: 17059911
    [No Abstract]   [Full Text] [Related]  

  • 16. Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
    Becker MA; MacDonald PA; Hunt BJ; Jackson RL
    Diabetes Obes Metab; 2013 Nov; 15(11):1049-55. PubMed ID: 23683134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allopurinol and mortality in hyperuricaemic patients.
    Luk AJ; Levin GP; Moore EE; Zhou XH; Kestenbaum BR; Choi HK
    Rheumatology (Oxford); 2009 Jul; 48(7):804-6. PubMed ID: 19447769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
    Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study.
    Shih HJ; Kao MC; Tsai PS; Fan YC; Huang CJ
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):328-333. PubMed ID: 28398294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.